Current Cancer Therapy Reviews最新文献_第10页

Adjuvant Approach to Mitigate the Adverse Effects of Cancer Treatments using Homeopathic Medicines 辅助方法减轻使用顺势疗法药物治疗癌症的不良反应

IF 0.6

Current Cancer Therapy Reviews Pub Date : 2022-05-12 DOI: 10.2174/1573394718666220512163517

Arun Kumar, Mahima Sharma, Suneel Prajapati, Pankaj Gupta

{"title":"Adjuvant Approach to Mitigate the Adverse Effects of Cancer Treatments using Homeopathic Medicines","authors":"Arun Kumar, Mahima Sharma, Suneel Prajapati, Pankaj Gupta","doi":"10.2174/1573394718666220512163517","DOIUrl":"https://doi.org/10.2174/1573394718666220512163517","url":null,"abstract":"\u0000\u0000Worldwide, cancer patients are facing problem with life-and-death decision due to the associated severe adverse and sometimes fatal effects of existing conventional treatments. Due to the severe adverse effects of existing therapies, effective cures are progressively explored for anticancer treatment.Mostly the conventional therapies are based upon nonspecific cellular destruction properties; therefore, a treatment approach is desired to reduce the toxic burden upon normal tissues. Among all alternative medicine systems, homeopathy is one of the most popular treatment for cancer patients globally due to its minimal side effects.\u0000\u0000\u0000\u0000In this present review, we have attempted to comprehend the literature reports of homeopathic medicine in cancer treatment.\u0000\u0000\u0000\u0000Homeopathy has also proved their adjuvant approach to minimize the symptomatic consequences of cancer. However, the insufficiency of evidence and lack of recurrence of the trials cause difficulty to draw any conclusive evidence about homeopathy as an adjuvant therapy. Based upon the etiology, genoprotective potential of homeopathic drugs was reviewed and found inconsequential evaluation and scanty literature.\u0000\u0000\u0000\u0000Hence, the present review gives a comprehensive summary of retrospective studies and suggests an integration of rational drug selection, standard protocols, and quantitative analysis for revealing the differential role and plausible application of homeopathy in better cancer management.\u0000","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45984646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Hospital incidence and medical costs of female breast cancer in Spain: a retrospective multicenter study 西班牙女性乳腺癌的住院发病率和医疗费用:一项回顾性多中心研究

IF 0.6

Current Cancer Therapy Reviews Pub Date : 2022-05-11 DOI: 10.2174/1573394718666220511115125

J. Darbà, A. Marsà

{"title":"Hospital incidence and medical costs of female breast cancer in Spain: a retrospective multicenter study","authors":"J. Darbà, A. Marsà","doi":"10.2174/1573394718666220511115125","DOIUrl":"https://doi.org/10.2174/1573394718666220511115125","url":null,"abstract":"\u0000\u0000Breast cancer is the most prevalent cancer type in women worldwide, causing the greatest number of cancer-related deaths. This study aimed to evaluate the use of healthcare resources associated with female breast cancer in Spain, to analyze trends in hospitalization and death rates, and the related direct medical costs.\u0000\u0000\u0000\u0000A retrospective multicenter study was designed analyzing records of hospital and ambulatory visits of women diagnosed with breast cancer in Spanish hospitals between 1 January 2005 and 31 December 2018.\u0000\u0000\u0000\u0000In total, 353,080 admission files were reviewed, mainly inpatient hospital admissions, corresponding to 299,585 individual patients. Median patient age was 59 years, 12.7% of admissions registered the presence of metastatic tumors and 15.7% registered unspecified secondary tumors. Mean in-hospital death rate was 3.0% for patients without a metastatic disease and 10.5% in patients with a metastatic disease, decreasing significantly over the study period. Total age-adjusted hospitalization rate increased between 2005 and 2011, and decreased after 2012. Mean direct medical cost was €3824 per outpatient visit, €3995 per hospital admission up to 3 days and €5001 per hospital admission over 3 days. Admission cost increased in patients with a metastatic disease and in those deceased during the hospitalization.\u0000\u0000\u0000\u0000This study supports previous findings regarding the relative increase in breast cancer incidence that could be attributed to the intensive screening, along with the reduction in the death rate. Mean direct medical cost in this study varied greatly with length of stay, presence of metastatic tumors and disease fatality.\u0000","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42145336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Theranostics and nanoparticular approaches for the treatment of oral squamous cell carcinoma 口腔鳞状细胞癌的治疗学和纳米粒子入路

IF 0.6

Current Cancer Therapy Reviews Pub Date : 2022-05-11 DOI: 10.2174/1573394718666220511114831

Sankha Bhattacharya

引用次数: 0

Current views on oncolytic adenoviruses for cancer therapy 溶瘤腺病毒用于癌症治疗的最新观点

IF 0.6

Current Cancer Therapy Reviews Pub Date : 2022-05-11 DOI: 10.2174/1573394718666220511115638

Sankha Bhattacharya

{"title":"Current views on oncolytic adenoviruses for cancer therapy","authors":"Sankha Bhattacharya","doi":"10.2174/1573394718666220511115638","DOIUrl":"https://doi.org/10.2174/1573394718666220511115638","url":null,"abstract":"\u0000\u0000Oncolytic viruses replicate and spread in tumors at the same time, resulting in increased cytotoxicity and the reversal of tumor immune suppression. Among other viruses, recombinant adenoviruses that replicated in tumor cells were clinically tested via intratumoral or systemic administration. Although oncolytic virus replication kills tumor cells on its own, it may also activate the immune system, which can aid in tumor control. Viruses can be modified to improve their selectivity and effectiveness. Adenovirus genomes can be easily designed to incorporate various tumor-targeting pathways and therapeutic transgenes to improve antitumor properties. Poor tumor targeting, intratumoral expansion, and virocentric immune responses are all linked to low efficacy. As a result, more effective oncolytic adenoviruses that can be used alone or in combination with chemotherapy or immunotherapy are needed. Oncolytic Adenovirus (OAds) has long been considered a potential biotherapeutic agent against various cancers due to its ability to replicate cancer cells while remaining dormant in healthy cells selectively. Several preclinical studies using genetic engineering technology have increased antitumor OAds in various cancers in recent years. Systemic OAds administration is hampered by poor targeting tropism to healthy tissues, low-level ad receptors on tumor cells, and pre-existing neutralizing antibodies. Various discoveries have been made to overcome these barriers, including stem cells, nanoparticles, polymer shielding, extracellular vesicles, hydrogels, and microparticles (MPs). These carriers may improve Oncolytic viruses’ therapeutic efficacy by improving transfection, circulatory survival, cellular interactions, specific targeting, and immune response. The structure and biology of adenoviruses, the different types of OAds, and the efficacy of different carriers in the systemic administration of OAds were all examined in this review.\u0000","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":"1 1","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41333363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent Updates on Folate Targeted Drug Delivery Systems in Cancer: A Mini Review 癌症中叶酸靶向药物递送系统的最新进展:综述

IF 0.6

Current Cancer Therapy Reviews Pub Date : 2022-05-08 DOI: 10.2174/1573394718666220508181053

Deepika Sharma, Manu Sharma, G. Bisht

引用次数: 0

Meet The Editorial Board Member 见见编委会成员

IF 0.6

Current Cancer Therapy Reviews Pub Date : 2022-05-01 DOI: 10.2174/157339471802220804153652

E. Bouffet

引用次数: 0

Gastric Cancer: A review of risk factors and new insights into treatment 癌症：危险因素综述及治疗新见解

IF 0.6

Current Cancer Therapy Reviews Pub Date : 2022-04-28 DOI: 10.2174/1573394718666220428105301

S. Azadbakht, P. Baharvand, M. Saki, Alireza Moayyedkazemi

引用次数: 0

Immunosuppressive function of intratumor red blood cells: An immunometabolic perspective 肿瘤内红细胞的免疫抑制功能:免疫代谢的观点

IF 0.6

Current Cancer Therapy Reviews Pub Date : 2022-04-28 DOI: 10.2174/1573394718666220428120818

C. Papadopoulos

引用次数: 3

In Silico Identification of Novel Quinoline-3-carboxamide Derivatives Targeting Platelet Derived Growth Factor Receptor 靶向血小板衍生生长因子受体的新型喹啉-3-甲酰胺衍生物的原位硅鉴定

IF 0.6

Current Cancer Therapy Reviews Pub Date : 2022-04-21 DOI: 10.2174/1573394718666220421111546

Ganesh S. Mhaske, A. Sen, Ashish P. Shah, R. Khiste, Ajit V. Dale, D. Sen

{"title":"In Silico Identification of Novel Quinoline-3-carboxamide Derivatives Targeting Platelet Derived Growth Factor Receptor","authors":"Ganesh S. Mhaske, A. Sen, Ashish P. Shah, R. Khiste, Ajit V. Dale, D. Sen","doi":"10.2174/1573394718666220421111546","DOIUrl":"https://doi.org/10.2174/1573394718666220421111546","url":null,"abstract":"\u0000\u0000Several computer-aided drug design (CADD)methods enable the design and development of novel chemical entities.Structure-based drug design (SBDD) and the knowledge of in silico methods enable the visualization of the binding process of ligands to targets and to predict the key binding pocket sites and affinity of ligands to their target macromolecules.\u0000\u0000\u0000\u0000The present study was carried out to identify novel N-2-amino-N-phenyl quinoline-3-carboxamide (AQCMs)derivatives targeting Platelet-derived growth factor receptor (PDGFR) to cure cancer using in silico approach.\u0000\u0000\u0000\u0000AQCMswere designed by using ChemAxon Marvin Sketch 5.11.5 software. SwissADME and admetSAR online webserver were used to predict physicochemical properties as well as the toxicity of compounds. Ligand-receptor interactions between quinoline-3-carboxamide derivatives with the target receptor (PDB:5GRN) were carried out using molecular docking technique by employing various softwares like AutoDock 1.1.2, MGL Tools 1.5.6, Discovery Studio Visualizer v20.1.0.19295, Procheck, ProtParam tool, and PyMOL.\u0000\u0000\u0000\u0000In silicoresults reveal that all designed compounds had acceptable pharmacokinetic properties, were found to be orally bioavailable, and less harmful. Molecules from 36 to 39 showed better docking scores as compared to standard drugs sunitinib and tasquinimod.\u0000\u0000\u0000\u0000Increase in binding energy and the number of H-bonds established by AQCMs with below 3.40 Å distance interactions allows a valuable starting point in order to optimize compounds for further investigation. Pharmacokinetics and toxicological profile build up the applicability of quinoline-3-carboxamide moiety as a potential new candidate for the cure of cancer that could help the medicinal chemists for additional extensive in vitro, in vivo chemical, and pharmacological investigations.\u0000","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44475115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anticancer Mechanism of D-limonene: An Updated Review and Therapeutic Possibilities d -柠檬烯的抗癌机制:最新综述和治疗可能性

IF 0.6

Current Cancer Therapy Reviews Pub Date : 2022-04-21 DOI: 10.2174/1573394718666220421112750

D. Mandal, T. Parija

{"title":"Anticancer Mechanism of D-limonene: An Updated Review and Therapeutic Possibilities","authors":"D. Mandal, T. Parija","doi":"10.2174/1573394718666220421112750","DOIUrl":"https://doi.org/10.2174/1573394718666220421112750","url":null,"abstract":"\u0000\u0000Despite remarkable advancement in screening, diagnosis, and treatment modalities cancer remains the second leading cause of death globally. Chemoprevention is considered to be a potential strategy for dealing with cancer incidence and mortality. The present demand for a less toxic well-tolerated natural anticancer compound that can be used for chemoprevention has drawn the attention towards D-limonene, which is a monocyclic monoterpene found in citrus oil. In recent years several in vitro and in vivo studies have supported the anticancer potential of D-limonene in various cancers. Although these studies have highlighted its course of action through immune modulation, anti-oxidant activity, apoptosis, autophagy, etc. various scientific pieces of evidence support the fact that it targets multiple pathways to inhibit cancer.\u0000\u0000\u0000\u0000The current review focuses on the molecular mechanisms underlying the anticancer activity of D-limonene and discusses its potential to be used as a cost-effective chemopreventive and chemotherapeutic drug alone or in combination with other drugs.\u0000\u0000\u0000\u0000Scientific databases like Web of Science, Scopus, PubMed, Google Scholar, PubMed Central etc have been used to review new and recent insights into the anticancer mechanism of D-limonene.\u0000\u0000\u0000\u0000In this review, we discussed the overall, significance of the anticancer mechanisms of D-limonene which include modulation of apoptosis, promotion of autophagy and inhibition of angiogenesis and metastasis. It also inhibits oncogenic signaling molecules and related transcription factors. Additionally, it also acts in combination with other anticancer compounds to inhibit cancer.\u0000","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43187812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1